FDC Limited , a prominent player in the pharmaceutical sector, has released its unaudited financial results for the second quarter and half-year ended September 30, revealing a mixed performance amid challenging market conditions.

Key Financial Highlights

Quarterly Performance Analysis

FDC Limited experienced a decline in both revenue and profitability for the quarter ended September 30, compared to the same period last year. The company's standalone revenue from operations decreased by 5.61% to ₹102,508.02 lakhs, down from ₹108,600.49 lakhs in Q2 FY2025. This decline was mirrored in the consolidated figures, with revenue falling by 5.54% to ₹103,773.60 lakhs.

The impact on profitability was more pronounced, with standalone profit after tax (PAT) declining by 31.71% to ₹12,571.32 lakhs, compared to ₹18,407.85 lakhs in the corresponding quarter of the previous year. On a consolidated basis, PAT dropped by 32.60% to ₹12,584.17 lakhs.

Half-Yearly Performance

Despite the quarterly setback, FDC Limited's half-yearly results showed some resilience. Standalone revenue for H1 FY2026 increased by 6.38% to ₹209,838.66 lakhs, up from ₹197,261.76 lakhs in H1 FY2025. Standalone PAT for the half-year also saw a modest increase of 4.78% to ₹26,897.42 lakhs.

However, the consolidated half-yearly figures painted a slightly different picture. Consolidated revenue for H1 FY2026 decreased marginally by 1.75% to ₹211,438.83 lakhs, while consolidated PAT declined by 7.59% to ₹26,897.25 lakhs compared to the same period last year.

Financial Position and Other Highlights

• The company recognized a fair value loss of ₹143.36 lakhs under other expenses in Q2 FY2026. However, for the half-year period, a net fair value gain of ₹1,905.36 lakhs was recorded under Other Income.
• Basic and diluted earnings per share for Q2 FY2026 stood at ₹7.72, down from ₹11.30 in Q2 FY2025.
• FDC Limited maintains a strong balance sheet with total assets of ₹287,821.00 lakhs as of September 30, on a standalone basis.

Management Commentary

Mohan A. Chandavarkar, Managing Director of FDC Limited, stated, "While we faced some headwinds in the second quarter, our half-yearly performance demonstrates the resilience of our business model. We remain committed to our strategic initiatives and are confident in our ability to navigate the current market challenges."

Outlook

As FDC Limited navigates through a challenging market environment, the company's focus on maintaining operational efficiency and leveraging its strong market position will be crucial. The pharmaceutical sector continues to evolve, and FDC's ability to adapt to changing market dynamics will be key to its future performance.

Investors and stakeholders will be watching closely to see how FDC Limited addresses the revenue and profitability challenges in the coming quarters, and whether the company can build on the positive aspects of its half-yearly performance to drive growth in the latter half of the fiscal year.

FDC Limited , a prominent pharmaceutical company, has announced a significant change in its top management. The company's Board of Directors has accepted the resignation of Vijay Dharmadatt Bhatt from his position as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective October 20, 2025. Simultaneously, the Board has appointed Vishal Shah as the new CFO and KMP, with his tenure commencing on October 24, 2025.

Resignation Details

Mr. Bhatt, in his resignation email, cited the pursuit of better prospects as the reason for his departure. The company acknowledged his valuable contributions during his tenure and expressed best wishes for his future endeavors.

New Appointment

The appointment of Vishal Shah as the new CFO and KMP was approved based on recommendations from the Nomination and Remuneration Committee and the Audit Committee. Mr. Shah brings a wealth of experience to his new role, with approximately 20 years of work in various finance portfolios within the pharmaceutical industry.

Key Information

Here's a summary of the key details regarding this management change:

The transition in the CFO position is a significant development for FDC Limited. Mr. Shah's extensive experience in various aspects of finance within the pharmaceutical industry suggests that he is well-positioned to contribute to the company's financial strategy and operations going forward.

FDC Limited has complied with the necessary regulatory requirements by disclosing this information under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015. The company's proactive approach in managing this transition demonstrates its commitment to maintaining transparency with its stakeholders and ensuring a smooth handover of financial leadership.